Medicare Enrolled
Dr. Rebecca Kosloff, MD
Hematology · Bonita Springs, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kosloff from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kosloff? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kosloff
Dr. Rebecca Kosloff is a hematology in Bonita Springs, FL, with 19 years in practice. Based on federal Medicare data, Dr. Kosloff performed 328,856 Medicare services across 7,286 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kosloff received a total of $6,709 from 69 pharmaceutical and/or device companies across 373 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kosloff is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 7% volume in FL$ $6,709 industry payments
Medicare Practice Summary
Medicare Utilization ↗328,856
Medicare services
Top 7% in FL for hematology
7,286
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~17,308 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 81,600 | $0 | $4 |
| Filgrastim injection (Zarxio) for white blood cells | 47,160 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 24,000 | $43 | $137 |
| Daratumumab injection (Darzalex) | 21,960 | $38 | $110 |
| Anti-nausea injection (aprepitant) | 21,190 | $1 | $5 |
| Azacitidine chemotherapy injection | 19,335 | $0 | $4 |
| Oxaliplatin chemotherapy injection | 16,878 | $0 | $12 |
| Iron infusion (Injectafer) | 16,500 | $1 | $3 |
| Epoetin alfa injection (Procrit) for anemia | 12,830 | $6 | $23 |
| Paclitaxel chemotherapy injection | 12,440 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 10,020 | $18 | $51 |
| Immune globulin infusion (Gammagard) | 7,468 | $36 | $108 |
| Iron sucrose injection (Venofer) | 4,600 | $0 | $5 |
| Complete blood count (CBC) with differential | 3,739 | $8 | $29 |
| Dexamethasone injection (steroid) | 3,724 | $0 | $3 |
| Blood draw (venipuncture) | 3,502 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,740 | $1 | $28 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,201 | $24 | $185 |
| Anti-nausea injection (ondansetron/Zofran) | 1,656 | $0 | $9 |
| Office visit, established patient (30-39 min) | 1,595 | $97 | $339 |
| Injection, fulvestrant, 25 mg | 1,190 | $8 | $132 |
| Injection, leucovorin calcium, per 50 mg | 1,037 | $3 | $12 |
| Drug injection, under skin or into muscle | 1,028 | $11 | $69 |
| Iron infusion (Monoferric) | 1,010 | $17 | $57 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 901 | $3 | $205 |
| Injection of additional new drug or substance into vein | 850 | $12 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 749 | $103 | $378 |
| Injection, fluorouracil, 500 mg | 673 | $2 | $7 |
| Office visit, established patient (20-29 min) | 535 | $67 | $239 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 455 | $49 | $189 |
| Injection, carboplatin, 50 mg | 428 | $2 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 413 | $23 | $84 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 313 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 298 | $16 | $56 |
| Administration of chemotherapy into vein, each additional hour | 285 | $22 | $79 |
| Injection, diphenhydramine hcl, up to 50 mg | 251 | $1 | $3 |
| Infusion into a vein for hydration, each additional hour | 243 | $10 | $42 |
| Injection, potassium chloride, per 2 meq | 240 | $0 | $4 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 238 | $57 | $206 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 236 | $17 | $59 |
| Infusion, normal saline solution , 1000 cc | 236 | $2 | $7 |
| Injection, zoledronic acid, 1 mg | 207 | $7 | $69 |
| Injection, cisplatin, powder or solution, 10 mg | 191 | $2 | $13 |
| Administration of additional new drug or substance into vein, 1 hour or less | 182 | $52 | $178 |
| Injection, magnesium sulfate, per 500 mg | 179 | $1 | $2 |
| Infusion into a vein for hydration, 31-60 minutes | 169 | $25 | $156 |
| Office visit, established patient, complex (40-54 min) | 148 | $139 | $474 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 143 | $26 | $89 |
| Injection of drug or substance into vein | 135 | $29 | $156 |
| New patient office visit (45-59 min) | 97 | $126 | $453 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 94 | $136 | $637 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 90 | $3 | $11 |
| New patient office visit, complex (60-74 min) | 84 | $166 | $585 |
| Administration of additional new drug or substance into vein using push technique | 57 | $45 | $170 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 55 | $1 | $7 |
| Red blood count, automated test | 52 | $4 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 50 | $16 | $56 |
| Automated urinalysis | 46 | $2 | $8 |
| Prothrombin time test (blood clotting) | 46 | $4 | $15 |
| Drawing of blood for a medical problem | 42 | $71 | $277 |
| Administration of chemotherapy into vein using push technique | 31 | $80 | $303 |
| Transitional care management services for problem of high complexity | 11 | $223 | $722 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
33.0% high complexity
63.8% medium
3.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,709
Total received (2018-2024)
Avg $958/year across 7 years
Bottom 47% in FL for hematology
69
Companies
373
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,697 (99.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12 (0.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,411
2023$1,233
2022$1,314
2021$988
2020$574
2019$519
2018$670
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$646
Celgene Corporation
$504
Merck Sharp & Dohme LLC
$364
BeiGene USA, Inc.
$316
Novartis Pharmaceuticals Corporation
$307
Astellas Pharma US Inc
$291
GENZYME CORPORATION
$261
Daiichi Sankyo Inc.
$216
PFIZER INC.
$188
GlaxoSmithKline, LLC.
$185
Merck Sharp & Dohme Corporation
$181
Genentech USA, Inc.
$176
ABBVIE INC.
$155
NanoString Technologies, Inc.
$154
Amgen Inc.
$154
E.R. Squibb & Sons, L.L.C.
$145
Incyte Corporation
$143
Gilead Sciences, Inc.
$143
Regeneron Healthcare Solutions, Inc.
$131
ARRAY BIOPHARMA INC
$122
Ethicon US, LLC
$121
Seagen Inc.
$117
Kite Pharma, Inc.
$115
Takeda Pharmaceuticals U.S.A., Inc.
$114
Myriad Genetic Laboratories, Inc.
$96
Karyopharm Therapeutics Inc.
$87
AstraZeneca Pharmaceuticals LP
$81
PharmaEssentia USA Corporation
$72
JAZZ PHARMACEUTICALS INC.
$67
SpringWorks Therapeutics, Inc.
$56
Rigel Pharmaceuticals, Inc.
$51
AbbVie Inc.
$50
Octapharma USA, Inc.
$50
SERVIER PHARMACEUTICALS LLC
$47
Ipsen Biopharmaceuticals, Inc
$46
ADC Therapeutics America, Inc.
$43
Heron Therapeutics, Inc.
$38
Pharmacyclics LLC, An AbbVie Company
$38
Exelixis Inc.
$33
Acrotech Biopharma LLC
$33
Lilly USA, LLC
$33
GE HEALTHCARE
$32
Aurobindo Pharma USA, Inc.
$29
Iovance Biotherapeutics, Inc.
$29
Mirati Therapeutics, Inc.
$28
Sobi, Inc
$28
PUMA BIOTECHNOLOGY, INC.
$27
Sysmex Inostics Inc
$26
Dendreon Pharmaceuticals LLC
$25
RECORDATI_RARE_DISEASES_INC.
$25
AbbVie, Inc.
$23
Tempus AI, Inc
$22
Immunomedics, Inc.
$20
AMAG Pharmaceuticals, Inc.
$20
Teva Pharmaceuticals USA, Inc.
$18
Horizon Pharma plc
$18
Array BioPharma Inc.
$18
Helsinn Therapeutics (U.S.), Inc.
$16
Sirtex Medical Inc
$16
Sumitomo Pharma America, Inc.
$15
Partner Therapeutics, Inc.
$14
Clovis Oncology, Inc.
$14
Bayer HealthCare Pharmaceuticals Inc.
$13
Spectrum Pharmaceuticals Inc.
$12
SECURA BIO, INC.
$12
Lexicon Pharmaceuticals, Inc.
$12
Blueprint Medicines Corporation
$12
Kyowa Kirin, Inc.
$11
Veracyte, Inc.
$4
Top 3 companies account for 22.6% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · Abraxane · Alecensa · Aliqopa · Amtagvi · Avastin · BELEODAQ · BENDEKA · BESREMI · BLENREP · BRAFTOVI · BRUKINSA · Beleodaq · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CEREZYME · CINVANTI · COPIKTRA · CYRAMZA · Cabometyx · Creon · DARZALEX · DOPTELET · ELAHERE · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ERLEADA · Enhertu · Erleada · FARESTON · FERAHEME · Folotyn · GAUCHER-DISEASE · GAVRETO · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · KRYSTEXXA · Kyprolis · LENVIMA · LIBTAYO · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Leukine · MEKINIST · MONJUVI · NERLYNX · NINLARO · NUWIQ · Neulasta · Nplate · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PANHEMATIN · PEMAZYRE · PRECISETUMOR · PROMACTA · PROSIGNA ASSAY · PROVENGE · Padcev · Perjeta · Phesgo · Pomalyst · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SANDOSTATIN LAR · SARCLISA · SHINGRIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · Sustol · TAGRISSO · TASIGNA · TECVAYLI · TEVIMBRA · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tibsovo · Trodelvy · VENCLEXTA · VONVENDI · WILATE · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zevalin · myChoice CDx · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
18
Per 100K population
2.3
County median income
$73,099
Nearest hospital
PHYSICIANS REGIONAL MEDICAL CENTER - PINE RIDGE
7.3 mi
7.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kosloff is a mixed practice specialist, with above-average Medicare volume (top 7% in FL), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kosloff experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Kosloff performed 81,600 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kosloff receive payments from pharmaceutical companies?
Yes. Dr. Kosloff received a total of $6,709 from 69 companies across 373 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kosloff's costs compare to other hematologys in Bonita Springs?
Dr. Kosloff's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kosloff) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Bonita Springs
Browse hematologys in Bonita Springs ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology